skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Life Sciences Report 2015 reveals the patent landscape behind big pharma’s ‘decade of intense research into treatments for orphan diseases’.

 

The looming public health crisis is well documented, but the truth about R&D spend on rare diseases over antibiotics was laid bare in a recent report by Marks & Clerk. Life Sciences Report 2015 reveals the patent landscape behind big pharma’s ‘decade of intense research into treatments for orphan diseases’.

While these treatments are beneficial to a small proportion of the population, “the approaching crisis in antibiotics resistance has the potential to be catastrophic for human healthcare”, says Marks & Clark partner Gareth Williams. By contrast, antibiotics suffer from an “extremely low” level of research and new antibiotics are even more affected.

Thanks to increasing pressure and governmental incentives this trend is changing – but slowly. Vaccines, whose relative cost occupies the middle ground between rare diseases and antibiotics, has also seen an uptick in patent filings. But how many people will be affected by this disproportionate allocation of resources over the next decade? Article sourced from Intellectual Property Magazine. Click here to read more…

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。